Poly (ADP-ribose) polymerase ('PARP') inhibitors, methods and pharmaceutical compositions for the treatment of neurological or cardiovascular tissue damage

摘要

This invention relates to compounds, pharmaceutical compositions, and methods of using compounds of the formula:or a pharmaceutically acceptable salt, hydrate, prodrug, or mixtures thereof, whereinY is alkylhalo, alkyl-CO-G, COG, a direct bond, C=O, O, NR11, or CR8;G is NR11R16, OR9, SR9, or R10;Z is O, S, or NR11;X is NR16, O, S, CR12R13, C=O, a bond, -CR12=CR13-, -C(R12R13)C(R14R15)-, or;Rhd 1, R2, R3, R4, R5, R6, R7, R8, R10, R12, R13, R14, or R15 are independently: hydrogen, halo, alkylhalo, hydroxy, C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl group, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, aryl, amino, alkylamino, nitro, nitroso, carboxy, or aralkyl;R9 is hydrogen, hydroxy, C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl group, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, aryl, amino, alkylamino, carboxy, or aralkyl;R11 or R16 are independently: hydrogen, halo, alkylhalo, hydroxy, C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl group, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, aryl, amino, alkylamino, carboxy, or aralkyl.